Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleAmanda Burgess, 59, from East Sussex, was diagnosed with colorectal cancer in April 2024 and joined the trial at The Royal Marsden in July (PA)An early trial has shown significant promise for a targeted treatment, ozekibart, when combined with chemotherapy for patients with advanced bowel cancer.The drug works by mimicking a natural protein to trigger the 'death' of cancer cells while largely sparing healthy tissue.The Phase I trial, led by the Royal Marsden NHS Foundation Trust, involved 45 patients whose advanced bowel cancer had worsened after prior treatments.Results indicated that tumours shrank in 20 per cent of patients, and the cancer ceased growing in almost 87 per cent of participants.One patient, 59-year-old Amanda Burgess, described the therapy as giving her a “new lease of life”, allowing her to spend more time with her family and her beloved dogs.In fullNew bowel cancer drug halts tumour growth in nine out of 10 patientsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Promising bowel cancer drug gives patient ‘new lease of life’
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleAmanda Burgess, 59, from East Sussex, was diagnosed with colorectal cancer in April 2024 and joined the trial at The Royal Marsden in July (PA)An early trial has shown significant promise for a targeted treatment, ozekibart, when combined with chemotherapy for patients with advanced bowel cancer.The drug works by mimicking a natural protein to trigger the 'death' of cancer cells while largely sparing healthy tissue.The Phase I trial, led by the Royal Marsden NHS Foundation Trust, involved 45 patients whose advanced bowel cancer had worsened after prior treatments.Results indicated that tumours shrank in 20 per cent of patients, and the cancer ceased growing in almost 87 per cent of participants.One patient, 59-year-old Amanda Burgess, described the therapy as giving her a “new lease of life”, allowing her to spend more time with her family and her beloved dogs.In fullNew bowel cancer drug halts tumour growth in nine out of 10 patientsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
